What type of drug is Panobinostat?

Panobinostat (Panobinostat) is a histone deacetylase inhibitor and a new drug in cancer treatment. Histone deacetylase inhibitors are a class of drugs that inhibit the growth and spread of tumor cells by affecting cellular chromatin structure, gene transcription, and expression.

The mechanism of action mainly involves the inhibition of histone deacetylase. Histone is a protein that regulates gene expression through its binding to DNA. Histone deacetylase participates in the deacetylation process of histones and affects gene activity. Cancer cells often exhibit abnormal gene expression patterns, and inhibition of histone deacetylase can adjust these abnormalities and block tumor cell proliferation and survival.

Pabinostat is specifically used to treat multiple myeloma, a hematologic malignancy caused by abnormal proliferation of plasma cells in the bone marrow. In patients with multiple myeloma, panobinostat produces significant effects against cancer cells through its unique mechanism of action.

However, like many anti-cancer drugs, panobinostat is also associated with some adverse reactions, including hematological toxicity, cardiotoxicity, etc. Therefore, when treating with panobinostat, doctors need to comprehensively consider the patient's overall health status and regularly monitor their response to ensure the best treatment effect. The research and application of panobinostat brings new hope to the field of cancer treatment and provides directions for future research.

Panobinostat is not currently on the market in China, so patients cannot purchase it domestically and need to purchase panobinostat through overseas channels. There are only panobinostat original drugs available abroad, mainly the European version of the Swiss Novartis original drug, which is expensive, as high as more than 40,000 yuan.